The effects of COVID-19 on pharmacotherapy in patients with chronic diseases
Autor(a) principal: | |
---|---|
Data de Publicação: | 2021 |
Outros Autores: | , , |
Tipo de documento: | Artigo |
Idioma: | por |
Título da fonte: | Research, Society and Development |
Texto Completo: | https://rsdjournal.org/index.php/rsd/article/view/23479 |
Resumo: | The COVID-19 pandemic, caused by a new strain of coronavirus, has created great challenges throughout the world. This disease has the power to develop complications, higher morbidity and mortality when compared to other diseases, and a higher prevalence of hospitalizations in patients with Systemic Arterial Hypertension (SAH) and Diabetes Mellitus (DM). This study aimed to evaluate the effects of COVID-19 on pharmacotherapy in patients with chronic diseases. This is a descriptive, exploratory research with a qualitative and quantitative approach, carried out at FAINOR's Health Clinic. The sample for this study consisted of 20 patients, with the inclusion criteria being patients with chronic diseases, exclusively SAH or DM who had COVID-19 disease. As exclusion criteria, patients who did not have the disease. The data were collected through a questionnaire applied in an electronic format. Of the patients diagnosed, about 50% had isolated DM, 20% had isolated hypertension, 30% had associated DM and hypertension, and 30% were obese/overweight. About 70% of these people developed sequelae from the coronavirus, such as dehydration, body aches, dry cough, forgetfulness, and Acute Renal Failure. Approximately 40% of these patients had serious drug interactions in their treatments for SAH and DM, as well as concomitant SARS-CoV-2 treatment. It was concluded from the data collected in the survey that for SAH and DM the questionnaire elicited responses that indicated that the pandemic COVID-19 did not generate noticeable changes in the pharmacotherapy of the participants. However, the virus reflected negatively on the general health condition of the patients, causing sequelae in many of them. |
id |
UNIFEI_77e53177bad45aabf578357608f02d2d |
---|---|
oai_identifier_str |
oai:ojs.pkp.sfu.ca:article/23479 |
network_acronym_str |
UNIFEI |
network_name_str |
Research, Society and Development |
repository_id_str |
|
spelling |
The effects of COVID-19 on pharmacotherapy in patients with chronic diseasesEl alcance del COVID-19 sobre la farmacoterapia en pacientes con enfermedades crónicasOs reflexos da COVID-19 na farmacoterapia em pacientes portadores de doenças crônicas COVID-19HipertensãoDiabetesFarmacoterapia.COVID-19HipertensiónDiabetesFarmacoterapia.COVID-19HypertensionDiabetesPharmacotherapy.The COVID-19 pandemic, caused by a new strain of coronavirus, has created great challenges throughout the world. This disease has the power to develop complications, higher morbidity and mortality when compared to other diseases, and a higher prevalence of hospitalizations in patients with Systemic Arterial Hypertension (SAH) and Diabetes Mellitus (DM). This study aimed to evaluate the effects of COVID-19 on pharmacotherapy in patients with chronic diseases. This is a descriptive, exploratory research with a qualitative and quantitative approach, carried out at FAINOR's Health Clinic. The sample for this study consisted of 20 patients, with the inclusion criteria being patients with chronic diseases, exclusively SAH or DM who had COVID-19 disease. As exclusion criteria, patients who did not have the disease. The data were collected through a questionnaire applied in an electronic format. Of the patients diagnosed, about 50% had isolated DM, 20% had isolated hypertension, 30% had associated DM and hypertension, and 30% were obese/overweight. About 70% of these people developed sequelae from the coronavirus, such as dehydration, body aches, dry cough, forgetfulness, and Acute Renal Failure. Approximately 40% of these patients had serious drug interactions in their treatments for SAH and DM, as well as concomitant SARS-CoV-2 treatment. It was concluded from the data collected in the survey that for SAH and DM the questionnaire elicited responses that indicated that the pandemic COVID-19 did not generate noticeable changes in the pharmacotherapy of the participants. However, the virus reflected negatively on the general health condition of the patients, causing sequelae in many of them.La pandemia del COVID-19, generada por una nueva cepa de coronavirus, planteó grandes retos alrededordel mundo. Comparándolaconotrasenfermedades, estapuededesarrollarcomplicaciones, mayormorbilidad y mortalidad y una mayorprevalencia de hospitalizacionesen pacientes conHipertensión Arterial Sistémica y Diabetes Mellitus. El objetivo de este estudiofueevaluarel alcance del COVID-19 sobre la farmacoterapia en pacientes conenfermedades crónicas. Esta es una investigacióndescriptiva, exploratoriacon enfoque cualitativo y cuantitativo que se llevó a cabo enelAmbulatorio de Salud de la FAINOR. La muestra de este estudiolacompusieron 20 pacientes, estableciéndose como criterio de inclusión a aquellosconenfermedades crónicas, exclusivamente HAS o DM que tuvieronlaenfermedad COVID-19. Y como criterio de exclusión a los pacientes que no tuvieronlaenfermedad. Los datos se recolectaron a través de una encuesta aplicada electrónicamente. Alrededordel 50% de los pacientes diagnosticados teníasólo DM, el 20% sóloHipertensión, el 30% DM y HAS asociadas y el 30% del total teníaobesidad/sobrepeso. Alrededordel 70% de esas personas después de infectarseconcoronavirusdesarrollaronsecuelas como deshidratación, dolorescorporales, tos seca, olvido e Insuficiencia Renal Aguda. Alrededordel 40% tuvointeracciones medicamentosas graves ensutratamiento para HAS y DM, como también, concomitantes coneltratamientodel SARS-CoV-2. Se concluye que losdatosrecogidos a través de laencuestaindican que la pandemia COVID-19 no generó grandes cambios para HAS y DM enla farmacoterapia de los participantes. Sin embargo, se percibe que elvirusimpactó negativamente lasalud general de los pacientes al dejarlessecuelas.A pandemia da COVID-19, ocasionada por uma nova cepa de coronavírus, gerou grandes desafios por todo o mundo. Essa doença tem o poder de desenvolver maiores complicações, em relação a outras doenças, e uma maior ocorrência de internações em pacientes com hipertensão arterial sistêmica e diabetes mellitus. Este estudo teve como objetivo avaliar os reflexos da COVID-19 na farmacoterapia em pacientes portadores de doenças crônicas. Tratou-se de uma pesquisa de campo, descritiva, exploratória e de abordagem qualitativa e quantitativa, realizada no Ambulatório de Saúde da FAINOR, em setembro de 2021. Compuseram a amostra deste estudo 20 pacientes, tendo como critério de inclusão portadores de doenças crônicas, exclusivamente, hipertensão e diabetes que tiveram a doença COVID-19. E como critério de exclusão pacientes que não tiveram a doença. Os dados foram coletados através de um questionário aplicado em formato eletrônico. Para a avaliação e interpretação dos dados obtidos foi recorrido ao método do discurso do sujeito coletivo. Dos pacientes diagnosticados, cerca de 50% apresentavam diabetes, 20% apresentavam hipertensão, 30% diabetes e hipertensão associadas e 30% apresentavam obesidade/sobrepeso. Cerca de 70% dessas pessoas desenvolveram sequelas pelo coronavírus, como desidratação, dores no corpo, tosse seca, esquecimento e Insuficiência Renal Aguda. Cerca de 40% possuíam interações medicamentosas graves em seus tratamentos crônicos, concomitante com o tratamento do SARS-CoV-2. Concluiu-se que, a pandemia do COVID-19 não gerou mudanças perceptíveis na farmacoterapia dos participantes hipertensos e diabéticos. No entanto, o vírus refletiu negativamente no estado geral de saúde dos pacientes fazendo com que muitos ficassem com sequelas.Research, Society and Development2021-12-11info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionapplication/pdfhttps://rsdjournal.org/index.php/rsd/article/view/2347910.33448/rsd-v10i16.23479Research, Society and Development; Vol. 10 No. 16; e236101623479Research, Society and Development; Vol. 10 Núm. 16; e236101623479Research, Society and Development; v. 10 n. 16; e2361016234792525-3409reponame:Research, Society and Developmentinstname:Universidade Federal de Itajubá (UNIFEI)instacron:UNIFEIporhttps://rsdjournal.org/index.php/rsd/article/view/23479/20894Copyright (c) 2021 Danielle Portugal Vieira; Nicolly Luz Pita; Tayanne Andrade dos Santos; Daianne Arruda Luzhttps://creativecommons.org/licenses/by/4.0info:eu-repo/semantics/openAccessVieira, Danielle PortugalPita, Nicolly Luz Santos, Tayanne Andrade dosLuz, Daianne Arruda 2021-12-20T11:03:07Zoai:ojs.pkp.sfu.ca:article/23479Revistahttps://rsdjournal.org/index.php/rsd/indexPUBhttps://rsdjournal.org/index.php/rsd/oairsd.articles@gmail.com2525-34092525-3409opendoar:2024-01-17T09:42:20.134589Research, Society and Development - Universidade Federal de Itajubá (UNIFEI)false |
dc.title.none.fl_str_mv |
The effects of COVID-19 on pharmacotherapy in patients with chronic diseases El alcance del COVID-19 sobre la farmacoterapia en pacientes con enfermedades crónicas Os reflexos da COVID-19 na farmacoterapia em pacientes portadores de doenças crônicas |
title |
The effects of COVID-19 on pharmacotherapy in patients with chronic diseases |
spellingShingle |
The effects of COVID-19 on pharmacotherapy in patients with chronic diseases Vieira, Danielle Portugal COVID-19 Hipertensão Diabetes Farmacoterapia. COVID-19 Hipertensión Diabetes Farmacoterapia. COVID-19 Hypertension Diabetes Pharmacotherapy. |
title_short |
The effects of COVID-19 on pharmacotherapy in patients with chronic diseases |
title_full |
The effects of COVID-19 on pharmacotherapy in patients with chronic diseases |
title_fullStr |
The effects of COVID-19 on pharmacotherapy in patients with chronic diseases |
title_full_unstemmed |
The effects of COVID-19 on pharmacotherapy in patients with chronic diseases |
title_sort |
The effects of COVID-19 on pharmacotherapy in patients with chronic diseases |
author |
Vieira, Danielle Portugal |
author_facet |
Vieira, Danielle Portugal Pita, Nicolly Luz Santos, Tayanne Andrade dos Luz, Daianne Arruda |
author_role |
author |
author2 |
Pita, Nicolly Luz Santos, Tayanne Andrade dos Luz, Daianne Arruda |
author2_role |
author author author |
dc.contributor.author.fl_str_mv |
Vieira, Danielle Portugal Pita, Nicolly Luz Santos, Tayanne Andrade dos Luz, Daianne Arruda |
dc.subject.por.fl_str_mv |
COVID-19 Hipertensão Diabetes Farmacoterapia. COVID-19 Hipertensión Diabetes Farmacoterapia. COVID-19 Hypertension Diabetes Pharmacotherapy. |
topic |
COVID-19 Hipertensão Diabetes Farmacoterapia. COVID-19 Hipertensión Diabetes Farmacoterapia. COVID-19 Hypertension Diabetes Pharmacotherapy. |
description |
The COVID-19 pandemic, caused by a new strain of coronavirus, has created great challenges throughout the world. This disease has the power to develop complications, higher morbidity and mortality when compared to other diseases, and a higher prevalence of hospitalizations in patients with Systemic Arterial Hypertension (SAH) and Diabetes Mellitus (DM). This study aimed to evaluate the effects of COVID-19 on pharmacotherapy in patients with chronic diseases. This is a descriptive, exploratory research with a qualitative and quantitative approach, carried out at FAINOR's Health Clinic. The sample for this study consisted of 20 patients, with the inclusion criteria being patients with chronic diseases, exclusively SAH or DM who had COVID-19 disease. As exclusion criteria, patients who did not have the disease. The data were collected through a questionnaire applied in an electronic format. Of the patients diagnosed, about 50% had isolated DM, 20% had isolated hypertension, 30% had associated DM and hypertension, and 30% were obese/overweight. About 70% of these people developed sequelae from the coronavirus, such as dehydration, body aches, dry cough, forgetfulness, and Acute Renal Failure. Approximately 40% of these patients had serious drug interactions in their treatments for SAH and DM, as well as concomitant SARS-CoV-2 treatment. It was concluded from the data collected in the survey that for SAH and DM the questionnaire elicited responses that indicated that the pandemic COVID-19 did not generate noticeable changes in the pharmacotherapy of the participants. However, the virus reflected negatively on the general health condition of the patients, causing sequelae in many of them. |
publishDate |
2021 |
dc.date.none.fl_str_mv |
2021-12-11 |
dc.type.driver.fl_str_mv |
info:eu-repo/semantics/article info:eu-repo/semantics/publishedVersion |
format |
article |
status_str |
publishedVersion |
dc.identifier.uri.fl_str_mv |
https://rsdjournal.org/index.php/rsd/article/view/23479 10.33448/rsd-v10i16.23479 |
url |
https://rsdjournal.org/index.php/rsd/article/view/23479 |
identifier_str_mv |
10.33448/rsd-v10i16.23479 |
dc.language.iso.fl_str_mv |
por |
language |
por |
dc.relation.none.fl_str_mv |
https://rsdjournal.org/index.php/rsd/article/view/23479/20894 |
dc.rights.driver.fl_str_mv |
https://creativecommons.org/licenses/by/4.0 info:eu-repo/semantics/openAccess |
rights_invalid_str_mv |
https://creativecommons.org/licenses/by/4.0 |
eu_rights_str_mv |
openAccess |
dc.format.none.fl_str_mv |
application/pdf |
dc.publisher.none.fl_str_mv |
Research, Society and Development |
publisher.none.fl_str_mv |
Research, Society and Development |
dc.source.none.fl_str_mv |
Research, Society and Development; Vol. 10 No. 16; e236101623479 Research, Society and Development; Vol. 10 Núm. 16; e236101623479 Research, Society and Development; v. 10 n. 16; e236101623479 2525-3409 reponame:Research, Society and Development instname:Universidade Federal de Itajubá (UNIFEI) instacron:UNIFEI |
instname_str |
Universidade Federal de Itajubá (UNIFEI) |
instacron_str |
UNIFEI |
institution |
UNIFEI |
reponame_str |
Research, Society and Development |
collection |
Research, Society and Development |
repository.name.fl_str_mv |
Research, Society and Development - Universidade Federal de Itajubá (UNIFEI) |
repository.mail.fl_str_mv |
rsd.articles@gmail.com |
_version_ |
1797052791122821120 |